Zacks Lowers AtriCure to Neutral (ATRC)
AtriCure (NASDAQ:ATRC) was downgraded by Zacks from an “outperform” rating to a “neutral” rating in a research report issued to clients and investors on Wednesday. They currently have a $19.20 price objective on the stock. Zacks‘s price objective would indicate a potential upside of 21.60% from the company’s current price.
Shares of AtriCure (NASDAQ:ATRC) traded down 2.15% during mid-day trading on Wednesday, hitting $15.45. The stock had a trading volume of 197,532 shares. AtriCure has a 1-year low of $9.02 and a 1-year high of $23.00. The stock has a 50-day moving average of $15.99 and a 200-day moving average of $17.35. The company’s market cap is $424.4 million.
AtriCure (NASDAQ:ATRC) last issued its quarterly earnings data on Thursday, July 24th. The company reported ($0.10) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.19) by $0.09. The company had revenue of $26.51 million for the quarter, compared to the consensus estimate of $25.03 million. During the same quarter in the prior year, the company posted ($0.09) earnings per share. The company’s quarterly revenue was up 29.8% on a year-over-year basis. On average, analysts predict that AtriCure will post $-0.76 earnings per share for the current fiscal year.
AtriCure, Inc, is a medical device company. The Company develops, manufactures and sells cardiac surgical ablation systems designed to create lesions, or scars, in cardiac, or heart, tissue and devices for the exclusion of the left atrial appendage.
To view Zacks’ full report, visit Zacks’ official website.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.